L Gedmintas1,2, E A Wright3,4, Y Dong3, E Lehmann5, J N Katz5,6,3,4, D H Solomon5,6,7, E Losina5,6,3,8. 1. Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, 75 Francis Street, Boston, MA, 02115, USA. lgedmintas@partners.org. 2. Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. lgedmintas@partners.org. 3. Department of Orthopedic Surgery, Orthopedic and Arthritis Center for Outcomes Research, Boston, MA, USA. 4. Harvard School of Public Health, Boston, MA, USA. 5. Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, 75 Francis Street, Boston, MA, 02115, USA. 6. Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. 7. Division of Pharmacoepidemiology and Pharmacoeconomics, Boston, MA, USA. 8. Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA.
Abstract
This study aims to determine what factors are associated with increased risk of fracture among patients with HIV, in particular whether an important medication used to treat HIV, tenofovir, is associated with fracture. Our study found that while co-infection with hepatitis C and markers of HIV severity were associated with fracture, tenofovir was not. INTRODUCTION: Growing evidence suggests that tenofovir disoproxil fumarate decreases bone density among patients with HIV, but there are conflicting reports as to whether this decrease in bone density translates to higher fracture risk. We aimed to determine what factors were associated with an increased risk of fracture for patients with HIV, in particular whether tenofovir is associated with elevated fracture risk. METHODS: We conducted a retrospective cohort study at two tertiary care hospitals in Boston, MA, between 2001 and 2012 to determine whether tenofovir use is associated with elevated all-site fracture risk, as compared to other antiretroviral medications. We also examined other potential factors associated with fracture among patients with HIV. RESULTS: We identified 1981 HIV-infected patients who had at some point used tenofovir and 682 patients who had not. The mean age was 43 years, and 72 % were male. The hepatitis C co-infection rate was 28 %, about 40 % had nadir CD4 count <200, and about 40 % had a history of an AIDS-defining illness. We did not find an association between risk of fracture and tenofovir disoproxil fumarate (TDF) (adjusted RR (aRR) 0.8, 95 % CI 0.6-1.1). However, co-infection with hepatitis C did increase risk of fracture (aRR 1.6, 95 % CI 1.1-2.3), as did nadir CD4 count <200 (aRR 3.1, 95 % CI 1.9-5.0) and history of AIDS-defining illness (aRR 1.6, 95 % CI 1.1-2.2). CONCLUSION: There was no association found between fracture and tenofovir use, but there were associations between co-infection with hepatitis C and markers of advanced HIV disease and fracture.
This study aims to determine what factors are associated with increased risk of fracture among patients with HIV, in particular whether an important medication used to treat HIV, tenofovir, is associated with fracture. Our study found that while co-infection with hepatitis C and markers of HIV severity were associated with fracture, tenofovir was not. INTRODUCTION: Growing evidence suggests that tenofovir disoproxil fumarate decreases bone density among patients with HIV, but there are conflicting reports as to whether this decrease in bone density translates to higher fracture risk. We aimed to determine what factors were associated with an increased risk of fracture for patients with HIV, in particular whether tenofovir is associated with elevated fracture risk. METHODS: We conducted a retrospective cohort study at two tertiary care hospitals in Boston, MA, between 2001 and 2012 to determine whether tenofovir use is associated with elevated all-site fracture risk, as compared to other antiretroviral medications. We also examined other potential factors associated with fracture among patients with HIV. RESULTS: We identified 1981 HIV-infectedpatients who had at some point used tenofovir and 682 patients who had not. The mean age was 43 years, and 72 % were male. The hepatitis C co-infection rate was 28 %, about 40 % had nadir CD4 count <200, and about 40 % had a history of an AIDS-defining illness. We did not find an association between risk of fracture and tenofovir disoproxil fumarate (TDF) (adjusted RR (aRR) 0.8, 95 % CI 0.6-1.1). However, co-infection with hepatitis C did increase risk of fracture (aRR 1.6, 95 % CI 1.1-2.3), as did nadir CD4 count <200 (aRR 3.1, 95 % CI 1.9-5.0) and history of AIDS-defining illness (aRR 1.6, 95 % CI 1.1-2.2). CONCLUSION: There was no association found between fracture and tenofovir use, but there were associations between co-infection with hepatitis C and markers of advanced HIV disease and fracture.
Authors: José L Casado; Carmen Santiuste; Monica Vazquez; Sara Bañón; Marta Rosillo; Ana Gomez; María J Perez-Elías; Carmen Caballero; José M Rey; Santiago Moreno Journal: AIDS Date: 2016-06-01 Impact factor: 4.177
Authors: Bryan Lau; A Richey Sharrett; Larry A Kingsley; Wendy Post; Frank J Palella; Barbara Visscher; Stephen J Gange Journal: Arch Intern Med Date: 2006-01-09
Authors: Georg Schett; Stefan Kiechl; Siegfried Weger; Angelo Pederiva; Agnes Mayr; Manuele Petrangeli; Friedrich Oberhollenzer; Rolando Lorenzini; Kurt Redlich; Roland Axmann; Jochen Zwerina; Johann Willeit Journal: Arch Intern Med Date: 2006 Dec 11-25
Authors: Alexandra Calmy; Christoph A Fux; Richard Norris; Nathalie Vallier; Cécile Delhumeau; Katherine Samaras; Karl Hesse; Bernard Hirschel; David A Cooper; Andrew Carr Journal: J Infect Dis Date: 2009-12-01 Impact factor: 5.226
Authors: Lydia Gedmintas; Elizabeth A Wright; Elena Losina; Jeffrey N Katz; Daniel H Solomon Journal: J Clin Endocrinol Metab Date: 2013-11-25 Impact factor: 5.958